A Betting Market Is Now Trading on Clinical Trials. The FDA's Former Chief Calls It a 'Breach of Scientific Conduct.'

Walter Ingaharro Jr. is living with metastatic pancreatic cancer. He is also, as of last month, the subject of a market.

Kalshi, a federally regulated U.S. prediction exchange, has begun listing contracts that pay out based on whether specific clinical drug trials succeed and whether the FDA approves them. The platform calls the program a "biotech prediction markets pilot." Ingaharro, who is enrolled in one of the trials Kalshi is now pricing, told the New York Times he only learned strangers were wagering on his treatment when a reporter called. "We're literally trying to stay alive," he said. "It's not a game. The introduction of gambling into the process really creates an ethical mess."

Robert Califf framed the practice more sharply. "Turning loose a betting market in an ongoing randomized clinical trial really is a breach of scientific conduct," he told the Times.

Kalshi's defense, on the record through spokesperson Jack Such and the company's own announcement, is that public contracts produce a "continuously updated, public probability that reflects the weight of the evidence rather than the preferred messaging of the trial sponsor." In other words, a market is a truth serum. Sponsors hype. Markets price. That argument does not survive what the price actually does once it exists.

The mechanism is short. A continuous price on an ongoing trial gives every enrolled patient a real-time signal about how the rest of the world is reading their odds. In a randomized study, the patients who know they are receiving the experimental drug and watch the contract drift downward now have a financialized reason to question whether they should remain in the trial. The reporting flagged that dynamic directly: enrollees could choose to drop out if a market priced against a positive outcome. A trial's data integrity depends on enrolled patients staying enrolled. A mass exit breaks the trial, and the market that priced the trial has just made the trial less reliable. The price then changes, and the loop runs again.

There is no gate for that loop. Kalshi is regulated by the Commodity Futures Trading Commission, a derivatives regulator that does not police patient welfare or scientific conduct. The FDA oversees trials but does not oversee whether third-party exchanges can list contracts on them. Trial sponsors could in principle object, but most have not.

Joshua Pederson, a Boston University humanities professor whose 12-year-old son has an aggressive tumor growing near his heart, made the patient-side argument in a Guardian op-ed. The prospect of replacing "our extremely qualified team of oncologists" with a prediction-market price feels "preposterous." He is not a market participant. He is the human being the market is pricing.

Kalshi's category keeps expanding. The same platform that priced election nights and the Super Bowl has now moved into a domain where the externality is human welfare. Reporting this week added texture the company did not choose to advertise: a Trump teleprompter operator was reported to have won more than $100,000 on Kalshi by betting on what he would say, on the same day the biotech pilot was announced. That detail is not the doorway. The story is that a single platform has entered a category, randomized clinical trials, where the regulator, the sponsor, and the platform itself each lack a rule for what happens when the price changes the thing it is pricing.

The trade press has been quicker than the regulators. PharmaVoice framed the pilot as a bet on biotech that could reshape how drugs are read by markets before they are read by clinicians. The Guardian's July coverage noted that the backlash has run ahead of any platform-level patient-protection rule. The forward question is not whether Kalshi's biotech market will be popular. The forward question is who, if anyone, decides that a contract on a specific trial has to come down. As of now, the answer is nobody.